vs

Side-by-side financial comparison of INDEPENDENCE REALTY TRUST, INC. (IRT) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.

INDEPENDENCE REALTY TRUST, INC. is the larger business by last-quarter revenue ($167.1M vs $123.8M, roughly 1.3× NATURES SUNSHINE PRODUCTS INC). INDEPENDENCE REALTY TRUST, INC. runs the higher net margin — 19.9% vs 3.3%, a 16.6% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs 3.8%). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs 2.0%).

Brandywine Realty Trust is a Philadelphia-based real estate investment trust (REIT) that invests in office buildings in Philadelphia, Washington, D.C., and Austin, Texas.

Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.

IRT vs NATR — Head-to-Head

Bigger by revenue
IRT
IRT
1.3× larger
IRT
$167.1M
$123.8M
NATR
Growing faster (revenue YoY)
NATR
NATR
+0.9% gap
NATR
4.7%
3.8%
IRT
Higher net margin
IRT
IRT
16.6% more per $
IRT
19.9%
3.3%
NATR
Faster 2-yr revenue CAGR
NATR
NATR
Annualised
NATR
5.6%
2.0%
IRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRT
IRT
NATR
NATR
Revenue
$167.1M
$123.8M
Net Profit
$33.3M
$4.1M
Gross Margin
72.5%
Operating Margin
4.3%
Net Margin
19.9%
3.3%
Revenue YoY
3.8%
4.7%
Net Profit YoY
3410.0%
1379.4%
EPS (diluted)
$0.14
$0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRT
IRT
NATR
NATR
Q4 25
$167.1M
$123.8M
Q3 25
$167.1M
$128.3M
Q2 25
$162.2M
$114.8M
Q1 25
$161.2M
$113.2M
Q4 24
$161.0M
$118.2M
Q3 24
$160.1M
$114.6M
Q2 24
$158.4M
$110.6M
Q1 24
$160.5M
$111.0M
Net Profit
IRT
IRT
NATR
NATR
Q4 25
$33.3M
$4.1M
Q3 25
$6.9M
$5.3M
Q2 25
$8.0M
$5.3M
Q1 25
$8.4M
$4.7M
Q4 24
$-1.0M
$-321.0K
Q3 24
$12.4M
$4.3M
Q2 24
$10.4M
$1.3M
Q1 24
$17.6M
$2.3M
Gross Margin
IRT
IRT
NATR
NATR
Q4 25
72.5%
Q3 25
73.3%
Q2 25
71.7%
Q1 25
72.1%
Q4 24
72.0%
Q3 24
71.3%
Q2 24
71.4%
Q1 24
71.2%
Operating Margin
IRT
IRT
NATR
NATR
Q4 25
4.3%
Q3 25
7.0%
Q2 25
3.7%
Q1 25
5.4%
Q4 24
3.8%
Q3 24
4.6%
Q2 24
5.1%
Q1 24
4.2%
Net Margin
IRT
IRT
NATR
NATR
Q4 25
19.9%
3.3%
Q3 25
4.1%
4.2%
Q2 25
5.0%
4.6%
Q1 25
5.2%
4.2%
Q4 24
-0.6%
-0.3%
Q3 24
7.7%
3.8%
Q2 24
6.5%
1.2%
Q1 24
10.9%
2.1%
EPS (diluted)
IRT
IRT
NATR
NATR
Q4 25
$0.14
$0.23
Q3 25
$0.03
$0.30
Q2 25
$0.03
$0.28
Q1 25
$0.04
$0.25
Q4 24
$-0.01
$-0.02
Q3 24
$0.05
$0.23
Q2 24
$0.05
$0.07
Q1 24
$0.08
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRT
IRT
NATR
NATR
Cash + ST InvestmentsLiquidity on hand
$23.6M
$93.9M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$3.5B
$161.6M
Total Assets
$6.0B
$261.1M
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRT
IRT
NATR
NATR
Q4 25
$23.6M
$93.9M
Q3 25
$23.3M
$95.6M
Q2 25
$19.5M
$81.3M
Q1 25
$29.1M
$86.5M
Q4 24
$21.2M
$84.7M
Q3 24
$17.6M
$78.7M
Q2 24
$21.0M
$68.7M
Q1 24
$21.3M
$77.8M
Total Debt
IRT
IRT
NATR
NATR
Q4 25
$2.3B
Q3 25
$2.3B
Q2 25
$2.2B
Q1 25
$2.3B
Q4 24
$2.3B
Q3 24
$2.3B
Q2 24
$2.3B
Q1 24
$2.3B
$2.1M
Stockholders' Equity
IRT
IRT
NATR
NATR
Q4 25
$3.5B
$161.6M
Q3 25
$3.5B
$166.7M
Q2 25
$3.4B
$163.7M
Q1 25
$3.5B
$167.1M
Q4 24
$3.4B
$161.0M
Q3 24
$3.4B
$162.6M
Q2 24
$3.4B
$156.4M
Q1 24
$3.4B
$159.7M
Total Assets
IRT
IRT
NATR
NATR
Q4 25
$6.0B
$261.1M
Q3 25
$6.1B
$264.8M
Q2 25
$6.0B
$254.9M
Q1 25
$6.0B
$252.7M
Q4 24
$6.1B
$240.9M
Q3 24
$5.9B
$245.3M
Q2 24
$5.9B
$235.8M
Q1 24
$6.0B
$247.3M
Debt / Equity
IRT
IRT
NATR
NATR
Q4 25
0.66×
Q3 25
0.66×
Q2 25
0.66×
Q1 25
0.65×
Q4 24
0.68×
Q3 24
0.68×
Q2 24
0.66×
Q1 24
0.67×
0.01×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRT
IRT
NATR
NATR
Operating Cash FlowLast quarter
$282.1M
$9.9M
Free Cash FlowOCF − Capex
$7.6M
FCF MarginFCF / Revenue
6.1%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
8.48×
2.41×
TTM Free Cash FlowTrailing 4 quarters
$28.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRT
IRT
NATR
NATR
Q4 25
$282.1M
$9.9M
Q3 25
$79.3M
$18.5M
Q2 25
$82.2M
$4.3M
Q1 25
$60.4M
$2.6M
Q4 24
$259.8M
$12.2M
Q3 24
$69.2M
$9.6M
Q2 24
$83.0M
$1.3M
Q1 24
$44.1M
$2.2M
Free Cash Flow
IRT
IRT
NATR
NATR
Q4 25
$7.6M
Q3 25
$16.8M
Q2 25
$3.0M
Q1 25
$1.5M
Q4 24
$10.0M
Q3 24
$7.9M
Q2 24
$-2.0M
Q1 24
$-1.5M
FCF Margin
IRT
IRT
NATR
NATR
Q4 25
6.1%
Q3 25
13.1%
Q2 25
2.6%
Q1 25
1.3%
Q4 24
8.5%
Q3 24
6.9%
Q2 24
-1.9%
Q1 24
-1.4%
Capex Intensity
IRT
IRT
NATR
NATR
Q4 25
1.9%
Q3 25
1.3%
Q2 25
1.2%
Q1 25
1.0%
Q4 24
1.9%
Q3 24
1.5%
Q2 24
3.0%
Q1 24
3.3%
Cash Conversion
IRT
IRT
NATR
NATR
Q4 25
8.48×
2.41×
Q3 25
11.51×
3.46×
Q2 25
10.22×
0.81×
Q1 25
7.23×
0.55×
Q4 24
Q3 24
5.60×
2.21×
Q2 24
8.02×
0.97×
Q1 24
2.51×
0.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IRT
IRT

Segment breakdown not available.

NATR
NATR

Other$68.1M55%
General Health Products$20.2M16%
Digestive Products$13.8M11%
Cardiovascular Products$12.1M10%
Personal Care Products$4.4M4%
Immunity Products$3.1M3%
Weight Management Products$2.1M2%

Related Comparisons